New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 4, 2014, Pages 483-491

  Burke, Stuart L ^a,b   Rose, Warren E ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

Combination therapy; Fosfomycin; Fusidic acid; Lipoglycopeptide; Omadacycline; Resistance; Staphylococcus aureus; Tedizolid

Indexed keywords

CEFTAROLINE; CEFTOBIPROLE; DALBAVANCIN; DAPTOMYCIN; FOSFOMYCIN; FUSIDIC ACID; ICLAPRIM; IMIPENEM; OMADACYCLINE; ORITAVANCIN; PLACEBO; TEDIZOLID; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

BACTERICIDAL ACTIVITY; DEVICE INFECTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG POTENCY; ENDOCARDITIS; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OSTEOMYELITIS; PHARMACEUTICAL CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PNEUMONIA; REVIEW; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS;

EID: 84893686655     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.876991     Document Type: Review

References (70)

1. Gould IM. Treatment of bacteraemia: meticillin-resistant Staphylococcus aureus (MRSA) to vancomycin-resistant S. aureus (VRSA). Int J Antimicrob Agents 2013;42(Suppl):S17-21
2. Levy DT, Steed ME, Rybak MJ, et al. Successful treatment of a left ventricular assist device infection with daptomycin non-susceptible methicillin-resistant Staphylococcus aureus: case report and review of the literature. Transpl Infect Dis 2012;14:E89-96
3. Brink AJ. Does resistance in severe infections caused by methicillin-resistant Staphylococcus aureus give you the creeps? Curr Opin Crit Care 2012;18:451-9
4. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52(3):e18-55
5. FDA. Guidance for industry: antibacterial therapies for patients with unmet medical need for the treatment of serious bacterial diseases. 2013.
6. Wolfe CR. Case report: treatment of chronic osteomyelitis. Clin Infect Dis 2011;52(Suppl 7):S538-41
7. Ho TT, Cadena J, Childs LM, et al. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother 2012;67(5):1267-70
8. Lin JC, Aung G, Thomas A, et al. The use of ceftaroline fosamil in methicillinresistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother 2013;19(1):42-9
9. Candiani G, Abbondi M, Borgonovi M, et al. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic. J Antimicrob Chemother 1999;44:179-92
10. Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol 2005;45:1279-87
11. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005;19(1):1407-15
12. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 2005;40:374-80
13. Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY antimicrobial surveillance program (2011). Diagn Microbiol Infect Dis 2013;75:304-7
14. Biedenbach DJ, Jones RN. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007). Diagn Microbiol Infect Dis 2009;64(2):177-84
15. Marbury T, Dowell JA, Seltzer E, Buckwalter M. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment. J Clin Pharmacol 2009;49(4):465-76
16. Bien P, Prokocimer P, Munoz K, Bohn J. Safety of multiple ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic [abstract P1089]. 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2009
17. Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 2013;309(6):559-69
18. Prokocimer P. Hematological effects of TR-701, linezolid and placebo administered for 21 days in healthy subjects. 48th Interscience Conference Antimicrobiology Agents Chemotherapy; 2008
19. Prokocimer P, Bien P, Deanda C, et al. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a Phase II study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2012;56(9):4608-13
20. Thomson KS, Goering RV. Activity of tedizolid (TR-700) against wellcharacterized MRSA strains of diverse epidemiological origin. Antimicrob Agents Chemother 2013;57(6):2892-5
21. Lepak AJ, Marchillo K, Pichereau S, et al. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model. Antimicrob Agents Chemother 2012;56(11):5916-22
22. Keel RA, Tessier PR, Crandon JL, Nicolau DP. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Antimicrob Agents Chemother 2012;56(8):4403-7
23. Rodriguez-Avial I, Culebras E, Betriu C, et al. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. J Antimicrob Chemother 2012;67(1):167-9
24. Agency EM. Available from: http://www. ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/medicines/002252/human-med-001584. jsp&mid= WC0b01ac058001d124 [Cited 27 May 2013]
25. Tefarlo [Package insert]. 2012. Available from: http://www.frx. com/pi/teflaro-pi.pdf [Cited 27 May 2013]
26. Lin JC, Aung G, Thomas A, et al. The use of ceftaroline fosamil in methicillinresistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother 2013;19:42-9
27. Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycinintermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother 2009;53:4712-17
28. Farrell DJ, Castanheira M, Mendes RE, et al. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010). Clin Infect Dis 2012;55(Suppl 3):S206-14
29. Noel GJ, Draper MP, Hait H, et al. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2012;56:5650-4
30. Pharmaceuticals P. Available from: http://www.paratekpharm.com/[Cited 27 May 2013]
31. Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 2003;26:511-32
32. Dunbar LM, Milata J, McClure T, Wasilewski MM. Comparison of the efficacy and safety of oritavancin frontloaded dosing regimens. Antimicrob Agents Chemother 2011;55:3476-84
33. Arhin FF, Moeck G, Draghi DC, et al. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Grampositive organisms from Europe: 2005-2008. Int J Antimicrob Agents 2010;36:474-6
34. Arhin FF, Sarmiento I, Parr TR Jr, Moeck G. Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus. Int J Antimicrob Agents 2012;39:159-62
35. Arhin FF, Sarmiento I, Moeck G. Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycinintermediate Staphylococcus aureus (hVISA). Int J Antimicrob Agents 2013;41:397-8
36. FDA issues complete response letter for oritavancin. 2008. Available from: http://www.fiercebiotech.com/pressreleases/fda-issues-complete- responseletter-oritavancin [Cited 28 May2013]
37. Belley A, Neesham-Grenon E, McKay G, et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother 2009;53:918-25
38. Polyzos KA, Mavros MN, Vardakas KZ, et al. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-Analysis. PLoS One 2012;7(8):e41870
39. Marcos LA, Camins BC. Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin. Antimicrob Agents Chemother 2010;54:5376-8
40. Joson J, Grover C, Downer C, et al. Successful treatment of methicillinresistant Staphylococcus aureus mitral valve endocarditis with sequential linezolid and telavancin monotherapy following daptomycin failure. J Antimicrob Chemother 2011;66:2186-8
41. Nace H, Lorber B. Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancin. J Antimicrob Chemother 2010;66(9):1315-16
42. Xiong YQ, Hady WA, Bayer AS, et al. Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillinresistant Staphylococcus aureus. Antimicrob Agents Chemother 2012;56:5528-33
43. Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008;52:37-44
44. Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008;46:647-55
45. Pharmaceuticals W. Tygacil [Package Insert]; 2012
46. McGovern PC, Wible M, El-Tahtawy A, et al. All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials. Int J Antimicrob Agents 2013;41:463-7
47. Ramirez J, Dartois N, Gandjini H, et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenemcilastatin for treatment of hospitalacquired pneumonia. Antimicrob Agents Chemother 2013;57:1756-62
48. Mandell L. Fusidic acid. Mandell, douglas and Bennetts principals and practice of infectious diseases. 7th edition. Elsevier Churchill Livingston, Philadelphia, PA, USA; 2010
49. Craft JC, Moriarty SR, Clark K, et al. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clin Infect Dis 2011;52(Suppl 7):S520-6
50. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011;52:285-92
51. Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009;48:713-21
52. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:674-80
53. Saleh-Mghir A, Muller-Serieys C, Dinh A, et al. Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2011;55:4589-93
54. Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011;53:158-63
55. Berti AD, Wergin JE, Girdaukas GG, et al. Altering the proclivity towards daptomycin resistance in methicillinresistant Staphylococcus aureus using combinations with other antibiotics. Antimicrob Agents Chemother 2012;56:5046-53
56. Rose WE, Schulz LT, Andes D, et al. Addition of ceftaroline to daptomycin after emergence of daptomycinnonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 2012;56:5296-302
57. Werth BJ, Vidaillac C, Murray KP, et al. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycinintermediate Staphylococcus aureus (VISA) and heterogeneous VISA. Antimicrob Agents Chemother 2013;57:2376-9
58. Berti AD, Sakoulas G, Nizet V, et al. Beta-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2013;57:5005-12
59. Steed ME, Werth BJ, Ireland CE, Rybak MJ. Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Antimicrob Agents Chemother 2012;56:5709-14
60. Avery LM, Steed ME, Woodruff AE, et al. Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 2012;56:5990-3
61. Steed ME, Vidaillac C, Rybak MJ. Novel daptomycin combinations against daptomycin-nonsusceptible methicillinresistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Antimicrob Agents Chemother 2010;54:5187-92
62. Garrigos C, Murillo O, Lora-Tamayo J, et al. Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2013;57(1):606-10
63. Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob Agents Chemother 2010;54:4329-34
64. Parra-Ruiz J, Bravo-Molina A, Pena-Monje A, Hernandez-Quero J. Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm. J Antimicrob Chemother 2012;67:2682-5
65. Kuli B, de Barbeyrac B, Dauchy FA, et al. In vitro activities of daptomycin, tigecycline, linezolid and eight other antibiotics, alone and in combination, against 41 Staphylococcus spp. clinical isolates from bone and joint infections. Int J Antimicrob Agents 2009;33:491-3
66. Rose WE, Poppens PT. Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus. J Antimicrob Chemother 2009;63:485-8
67. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 2009;34:506-15
68. Pulcini C, Bush K, Craig WA, et al. Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis 2012;54(2):268-74
69. Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008;46:1069-77
70. Miro JM, Entenza JM, Del Rio A, et al. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillinsusceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 2012;56(8):4511-15